Skip to content

Study · Non-randomized trial · 2014

2 results

[Neuroprotective treatment of chronic cerebrovascular insufficiency].

Anisimova AV, Kolesnikova TI, Iutskova EV, Galkin SS

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova1 Jan 2014Cited by 1 (Europe PMC)

PMID25176263 (opens in a new tab)PepBankPUB-25176263
Publisher pageAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In patients with chronic brain ischemia, cerebrolysin improved erythrocyte morpho-densitometric characteristics.

    In plain wordsIn patients with chronic brain ischemia, cerebrolysin improved measured red blood cell characteristics.

    Peptide
    Cerebrolysin
    Outcome
    Not applicableErythrocyte morpho-densitometric characteristics
    Study

    n: not reported in source

    Outcome group
    Cytoskeleton and cell structure · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Authors found the additional mechanisms of cerebrolysin action resulted in the improvement of morpho-densitometric characteristics of erythrocytes and hemorheological properties important for capillary blood flow.
    3 context sentences
    Summary · context
    To study the efficacy of cerebrolysin in 300 patients with chronic brain ischemia (CBI), I and II stages.
    Summary · context
    The main group consisted of 195 patients with CBI, I stage and 105 patients with CBI, II stage.
    Summary · context
    Patients of the control group (45 patients) did not receive cerebrolysin.
  2. 02HumanNon-randomized trialEfficacy outcome

    In patients with chronic brain ischemia, cerebrolysin improved hemorheological properties important for capillary blood flow.

    In plain wordsIn patients with chronic brain ischemia, cerebrolysin improved blood flow properties relevant to small vessels.

    Peptide
    Cerebrolysin
    Outcome
    Not applicableHemorheological properties
    Study

    n: not reported in source

    Outcome group
    Vascular function · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Authors found the additional mechanisms of cerebrolysin action resulted in the improvement of morpho-densitometric characteristics of erythrocytes and hemorheological properties important for capillary blood flow.
    3 context sentences
    Summary · context
    To study the efficacy of cerebrolysin in 300 patients with chronic brain ischemia (CBI), I and II stages.
    Summary · context
    The main group consisted of 195 patients with CBI, I stage and 105 patients with CBI, II stage.
    Summary · context
    Patients of the control group (45 patients) did not receive cerebrolysin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.